Accessibility Menu
E-therapeutics Plc logo

E-therapeutics Plc(LSE) ETX

This security has been delisted. This page is retained for historical reference.

E-therapeutics Plc last closing stock price
MetricPriceDate
Last closeGBX 9.002024-05-08
E-therapeutics Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.91%GBX 9.882024-04-30
1 month-22.08%GBX 11.552024-04-08
3 month-40%GBX 15.002024-02-08
Year to date+9.22%GBX 8.242023-12-29
1 year-30.9%GBX 13.032023-05-09
3 year-69.23%GBX 29.252021-05-07
5 year+328.57%GBX 2.102019-05-10
Since inception-86.67%GBX 0.682007-11-28

ETX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

ETX Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-4337.74%

Net Income Margin

-3511.32%

Return on Equity

-40.58%

Return on Capital

-60.76%

Return on Assets

-44.72%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

£522.00K

Operating Income

-£24.03M

EBITDA

-£23.42M

Operating Cash Flow

-£18.10M

Capital Expenditure

-£560.00K

Free Cash Flow

-£18.66M

Cash & ST Invst.

£20.67M

Total Debt

£710.00K

E-therapeutics Plc Performance Analysis

E-therapeutics Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-01-31GBP 477,000N/A
20232023-01-31GBP 475,000-0.4%
20242024-01-31GBP 318,000-33.1%
20252025-01-31GBP 0N/A
E-therapeutics Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-07-31N/A
Q42023-01-31-39.0%
Q22023-07-31-11.1%
Q42024-01-31-1.3%
E-therapeutics Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-01-31GBP -0.02N/A
20232023-01-31GBP -0.02-6.7%
20242024-01-31GBP -0.0224.0%
20252025-01-31GBP -0.025.2%
E-therapeutics Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-07-3128.2%
Q42023-01-31-8.1%
Q22023-07-31-20.0%
Q42024-01-312.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2023YOY CHG

Revenue

£158.00K

N/A

Gross Profit

£158.00K

+190.8%

Gross Margin

100.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

34

N/A

Net Income

-£5.57M

-5.5%

EBITDA

-£6.62M

-9.3%

Quarterly Fundamentals

Name
Q4 2023YOY CHG

Total Cash

£20.67M

-22.5%

Total Debt

£710.00K

+3.5%

Accounts Receivable

£0.00

-100.0%

Inventory

£0.00

N/A

Long Term Debt

£317.00K

+7.5%

Short Term Debt

£393.00K

-49.7%

Return on Assets

-44.72%

N/A

Return on Invested Capital

-61.83%

N/A

Free Cash Flow

-£4.25M

+24.5%

Operating Cash Flow

-£4.01M

+14.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
REDX.LRedx Pharma Plc
£0.15+31.58%
MTPH.LMidatech Pharma plc
£0.18+1794.74%
C4XD.LC4X Discovery Holdings plc
£0.12+27.32%
OKYO.LOKYO Pharma Limited
£0.01-24.32%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.